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Tumour hypoxia has been shown to increase mutation rate, angiogenesis, and metastatic potential, and decrease response to
conventional therapeutics. Improved tumour oxygenation should translate into increased treatment response. Exogenous
recombinant erythropoietin (rEpo) has been recently shown to increase tumour oxygenation in a mammary carcinoma model. The
mechanism of this action is not yet understood completely. The presence of Epo and its receptor (EpoR) have been demonstrated
on several normal and neoplastic tissues, including blood vessels and various solid tumours. In addition, rEpo has been shown in two
recent prospective, randomized clinical trials to negatively impact treatment outcome. In this study, we attempt to characterize the
direct effects of rEpo on tumour growth and angiogenesis in two separate rodent carcinomas. The effect of rEpo on R3230 rat
mammary adenocarcinomas, CT-26 mouse colon carcinomas, HCT-116 human colon carcinomas, and FaDu human head and neck
tumours, all of which express EpoR, was examined. There were no differences in tumour growth or proliferation (measured by Ki-67)
between placebo-treated and rEpo-treated tumours. In the mammary window chamber, vascular length density (VLD)
measurements in serial images of both placebo-treated and Epo-treated rats revealed no difference in angiogenesis between the
Epo-treated tumours and placebo-treated tumours at any time point. These experiments are important because they suggest that the
recent clinical detriment seen with the use of Epo is not due to its tumour growth effects or angiogenesis. These studies also suggest
that further preclinical studies need to examine rEpo’s direct tumour effects in efforts to improve the therapeutic benefits of Epo in
solid tumour patients.
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Low oxygen tension (pO2) promotes the selection of cells with
reduced apoptotic potential (Graeber et al, 1996), increases the
frequency of mutation (Reynolds et al, 1996), induces genes
promoting angiogenesis (Dachs and Chaplin, 1998) and decreases
radiosensitivity (Bedford and Mitchell, 1974). Clinically, tumour
hypoxia is associated with poorer outcome. A variety of
approaches have been used to reduce tumour hypoxia with the
goal of improving the therapeutic response to chemotherapy and/
or radiation therapy. A recent promising approach in preclinical
models involves the administration of exogenous recombinant
erythropoietin (rEpo) (Blackwell et al, 2003). Erythropoietin is a
glycoprotein growth factor that is essential for erythroid pre-
cursors to mature into red blood cells by stimulating growth and
preventing apoptosis (Krantz, 1991). It is a clinically important
member of the growth factor family, in that it is produced
endogenously in the human body and it may be given exogenously
in the human recombinant form to treat the anemia associated
with several chronic diseases. However, there have been several
reports suggesting that both Epo and EpoR can be expressed in
various neoplastic tissues, raising the possibility of autocrine
pathways. A randomized, placebo-controlled trial of rEpo in
nonanemic metastatic breast cancer patients was terminated early
because of an unexpectedly higher mortality rate in the group
receiving rEpo (Leyland-Jones, 2003). Also, a recent trial involving
patients with head and neck cancer found that rEpo did not
improve the efficacy of standard therapy (Henke et al, 2003).
Although the initial results from these two trials are disappointing,
their design fails to define a biologic mechanism for why rEpo
might lessen treatment effects. This preclinical study examines
rEpo’s effect on tumour growth and proliferation in two rodent
tumour lines and two human tumour lines, as well as its effects on
tumour angiogenesis.
MATERIALS AND METHODS
Animals
Female BALB/C mice (National Cancer Institute, Washington, DC,
USA) were used in the CT-26, HCT-116, and FaDu flank tumour
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sstudies. Female Fischer 344 rats (Charles River Laboratories,
Raleigh, NC, USA) were used for the R3230 flank tumour studies
and the mammary window chamber experiments. Tumour cells
were injected into the subcutis of the right quadriceps muscle for
flank tumours. Following injection of tumour cells or mammary
window surgery, the animals were allowed free access to food and
water ad libitum. All procedures and experiments were approved
by the Duke Institutional Animal Care and Use Committee.
Cell culture
R3230 (rat mammary adenocarcinoma) and GFP-R3230 (R3230
tumour cells constituitively transfected with green fluorescence
protein; as described in (Huang et al, 1999)) tumour cells were
maintained in DMEM (Sigma, St Louis, MO, USA) medium. CT-26
(murine colon adenocarcinoma) tumour cells were maintained in
RPMI (Sigma, St Louis, MO, USA). HCT-116 (human colon
carcinoma) tumour cells were maintained in McCoy’s 5A medium
(Sigma). FaDu (human head and neck carcinoma) were main-
tained in MEM supplemented with 1% sodium pyruvate and 1%
amino-acid solution. All media was supplemented with 10% FBS
(Sigma) and 1% penicillin/streptomycin (Sigma).
rEpo administration and hematocrit measurements
Animals in all studies were administered rEpo (Procritt, Ortho-
Biotech, Raritan, NJ, USA) as a 100unitml
 1 (120units¼1mg
EPO) solution in 0.9% NaCl via an injection into the subcutis of the
nape of the neck at a dose of 2000unitskg
 1 thrice per week. This
dosing is similar to a rEpo dose of 60000–100000IUdose
 1 in
humans, as referenced in previous work (Blackwell et al, 2003).
Hematocrit was determined in all animals by collecting 50mlo f
blood in a capillary tube from a tail vein of anesthesized animals,
then centrifuging for 1min and calculating hematocrit from the
ratio of the length of packed RBC’s to that of plasma.
Tumour volume
In rats, tumours were measured transversely and the volume
calculated using the formula:
Volume ¼greatesttransversedimension
 ðorthogonaltransversedimensionÞ
2 p=6
where all dimensions are in mm. In mice, tumour volume was
determined by the formula:
Volume ¼ length width height p=6
where all linear dimensions are in mm.
Epo receptor and Ki-67 immunohistochemistry
Standard immunohistochemical techniques were used to stain for
both EpoR and Ki-67. Briefly, IHC was performed using 10mm
serial sections of frozen tissue. Sections were fixed in 41C cold
acetone for 10min. After endogenous peroxidase activity was
quenched with 3% hydrogen peroxide for 15min, tumour sections
were blocked with 10% donkey serum for 15min. Sections were
incubated in primary antibodies (anti-EpoR (M-20), 1:200 (Santa
Cruz Biotechnology, Santa Cruz CA, USA); anti-Ki-67, 1:1000
(Novacastra, UK)) overnight at 41C. The location of the antibody
reactions was visualized with 3, 30-diaminobenzidine tetrahy-
drochloride (Sigma). For Ki-67 staining, four representative fields
at  40 objective taken from one tumour in each of six animals in
both the control and Epo-treatment group were measured.
Proliferation index was calculated by manually counting the ratio
of Ki-67-positive nuclei to total number of nuclei in each field, and
the average proliferation index for each tumour was calculated.
Mammary window chamber assay
The method used is the same as that described by Shan et al
(2003). The assay is an orthotopic variation of the dorsal skin fold
window chamber, which is the gold standard for serially measuring
in vivo angiogenesis. The epidermis around either the right third
or fourth nipple was removed, leaving an intact nipple and
surrounding subcutaneous tissue. The nipple was then removed at
its base, exposing the nipple sinus. A 1mm
3 piece of Gelfoam
(Pharmacia & Upjohn, Kalamazoo, MI, USA) soaked in 3mlo fa n
R3230-GFP cell suspension of concentration 2 10
6 cellsml
 1
(total of 6000 tumour cells) was inserted into the nipple sinus. This
was then covered with an acrylic window, which was sutured in
place.
Intravital microscopy
The mammary windows were imaged serially using a Carl Zeiss
MPS intravital microscope (Carl Zeiss, Hanover, MD, USA) every
other day, starting on postoperative day 2 and ending on
postoperative day 14. The microscope is equipped with a color
video camera (Carl Zeiss ZVS-3C75DE) connected to a PC
computer with a frame grabber and Scion Image software (Scion
Corporation, Frederick, MD). Fluorescence epi-illumination was
provided with a 100W mercury-arc lamp (AttoArc HBO, Carl Zeiss
Inc, USA) and a FITC filter (excitation 450–490nm and emission
520nm). Images were obtained at low magnification (objective
 5) and analyzed using Scion Image software. Vascular length
density (VLD) was calculated for each image by an observer
unaware of the treatment group.
Figure 1 EpoR status of tumour cell lines. Shown in (A) is an EpoR Western blot on all tumour cell lines used in this study. Positive staining is seen in all
the tumour cell lines. Also shown are H&E (B), negative IgG control (C), and EpoR (D) staining of a representative R3230 flank tumour section taken with a
 40 objective.
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The data on hematocrit, tumour volumes, and VLD were analyzed and
treatment groups compared using t-test for independent means. In all
analyses, two-sided P-values less than 0.05 was considered significant.
RESULTS
R3230, CT-26, HCT-116, and FaDu tumours express Epo
receptor
To establish relevance for this study, we determined the EpoR
status of each of the four tumour cell lines used. All four tumour
cell lines used in this experiment expressed Epo receptor by
Western blot (Figure 1A). This was confirmed by immunohisto-
chemical staining for EpoR. Interestingly, the strongest staining for
the receptor was in perinecrotic regions (Figure 1B).
Epo increases hematocrit
In the tumour growth studies, baseline hematocrit of mice was
46.571.5%. Treatment with Epo produced a hematocrit of
60.973.1 vs 46.772.1% in the control group after 14 days
(Po0.05). In the mammary window chamber experiments, EPO
significantly increased the baseline hematocrit (45.872.6) of
treated rats by 36% after 8 days and 40% at 14 days compared
to placebo-treated rats (P¼3.2 10
 8 and 4.3 10
 9 at days 8 and
14, respectively).
Epo does not promote tumour growth or proliferation rate
Tumour growth was observed in all rats transplanted with R3230
tumour cells and mice transplanted with CT-26, HCT-116, and
FaDu tumour cells. Tumour volumes were similar between the
EPO-treated and control groups in each of the four tumour cell
lines throughout the length of the study (Figure 2A–D). As
measured by Ki-67 immunohistochemical staining, there was no
statistical difference between the mean proliferation indices
between the EPO-treated and control groups (Figure 3) in any of
the tumour cell lines.
Epo does not stimulate tumour angiogenesis
There was no statistical difference in VLD between the EPO-treated
and control groups (Figure 4) at any timepoint (P40.05 at all
timepoints). All 20 rats tolerated the surgery well and were healthy
immediately postoperatively. At postoperative day 14, 14 of 20 rats
retained their mammary windows and had tumours that could be
visualized. This represents a success rate of 70%, consistent with
that of Shan (Shan et al, 2003). Six animals were unevaluable due
to: (1) rats that pulled off their windows (n¼2), (2) lack of tumour
growth (n¼3), or (3) infection/inflammation that prevented
tumour visualization (n¼1).
DISCUSSION
Recombinant Epo has recently been shown to improve tumour
oxygenation; its mechanism has not been determined. Tumour
oxygenation is dependent on a delicate balance between oxygen
delivery and oxygen consumption. Previous preclinical work in
this area, all done in vitro, has implicated rEpo as promoting
tumour growth (Westenfelder and Baranowski, 2000; Yasuda et al,
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Figure 2 Volume of tumours grown in BALB/C mice and Fischer 344
rats. CT-26 flank tumours (A) were grown in the right flank of female
BALB/C mice, R3230Ac flank tumours (B) were grown in the right flank of
female Fischer 344 rats, and FaDu (C) and HCT-116 (D) flank tumours
were grown in the right flank of female athymic mice. rEpo was
administered thrice weekly at dose of 2000unitskg
 1 for a total of six
doses of rEpo after tumours reached 100–200mm
3. Control-treated and
rEpo-treated tumour volumes were similar for all tumour types. Shown are
mean values7standard error of the mean (s.e.m.). T-test for independent
samples with two-tailed P-value.
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s2002) and/or being proangiogenic (Anagnostou et al, 1990; Carlini
et al, 1995; Ribatti et al, 1999; Acs et al, 2001; Yasuda et al, 2002).
However, no studies have looked at the in vivo effects of
therapeutic levels of rEpo on these two processes.
Several studies have suggested that Epo might stimulate
angiogenesis by acting to promote proliferation and/or migration
of endothelial cells (Anagnostou et al, 1990; Ribatti et al, 1999),
inhibiting apoptosis of endothelial cells (Carlini et al, 1999), or by
increasing MMP-2 secretion (Ribatti et al, 1999). rEpo has also
been shown to increase the number of circulating endothelial cells
and endothelial cell progenitors in preclinical models (Monestiroli
et al, 2001) and human breast cancer and lymphoma models
(Mancuso et al, 2001). Our studies demonstrate the importance of
in vivo modeling of rEpo’s effects, as we found no effects of rEpo
on tumour cell proliferation, tumour growth or angiogenesis.
Previous rEpo study results may be limited in their application
by the fact that they examined the effects of rEpo on one particular
cell line. In addition, previous studies used supratherapeutic
concentrations of recombinant Epo (5–100Uml
 1; Carlini et al,
1995), as compared to levels of Epo achieved clinically to correct
hematocrit (1.7–3.6Uml
 1; (Carlini et al, 1995)). Also, the
expression of Epo receptor on the tumour or endothelial cell line
that was used was not determined and/or the rEpo was
administered over a short period of time.
Our study is strengthened by the fact that we used four separate
tumour lines that express the Epo receptor and treated the animals
over an extended period. While the aim of this study was to
determine the effects of exogenous rEpo on two biologic processes
that directly affect tumour oxygenation (tumour growth and
angiogenesis), intra-tumoural production of Epo might also
influence tumour behavior in an autocrine/paracrine fashion.
Evidence for a functional Epo-EpoR system has been reported by
several groups: intratumoural and intraperitoneal injections of
solube EpoR or neutralizing monoclonal antibody to EpoR
resulted in tumour growth delay and inhibition of angiogenesis
(Yasuda et al, 2001, 2003; Arcasoy et al, 2002).
There have been no reports to date precisely analyzing the
angiogenic potential of therapeutic rEpo in an in vivo tumour
model. Our laboratory has extensively utilized the rodent dorsal
skin flap window chamber model in determining real-time,
sequential angiogenic effects of various agents (Li et al, 2000). A
limitation of the dorsal skin fold model, however, has been the
necessity of growing tumours in an ectopic site. Recently, our
laboratory has developed an orthotopic breast window, as
described by Shan (Shan et al, 2003). It has been established that
tumour microenvironment plays an influential role in the behavior
of the tumour itself and that tumours originating from different
tissues differ in their phenotypes, biological behaviors, and
responses to therapeutic agents (Fidler et al, 1994). When tested
in this highly translational in vivo model, rEpo did not
demonstrate any proangiogenic activity.
Finally, our studies offer insight into possible clinical effects of
rEpo on patients receiving the drug to treat anemia. Two recent
clinical trials (Henke et al, 2003; Leyland-Jones, 2003) have
suggested that rEpo might negatively impact treatment outcome in
cancer patients receiving chemotherapy. Additionally, in vitro
evidence suggests that rEpo may induce a cytoprotective
phenotype in certain tumour types, which could translate into
resistance to certain chemotherapeutics (Belenkov et al, 2004;
McBroom et al, 2005). However, a recent meta-analysis of rEpo
used in both patients with anemia and without anemia suggests a
strong trend towards a survival advantages in favor of the use of
rEpo (Bohlius et al, 2005). Although not combined with
chemotherapy or radiation therapy, the present study is the first
to provide preclinical in vivo insight into this seemingly confusing
clinical situation. In addition, our study suggests that recent
clinical results using rEpo in nonanemic patients may not be due
to the direct effects of the drug on the tumour, as we did not detect
any tumour growth enhancement with rEpo. Our findings warrant
further preclinical and clinical investigation of rEpo in order to
further clarify the risks of its use as well as optimize its known
benefits.
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Figure 3 Effect of rEpo on proliferation rate of tumour cells. Sections
were taken from (A) CT-26, (B) R3230, (C) FaDu, and (D) HCT-116
tumours and stained for Ki-67. There was no statistical difference between
the mean proliferation index of the rEpo-treated group and that of the
control-treated group in any tumour model (P¼0.14, 0.23, 0.09, and 0.11,
respectively).
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